Skip to main content

Table 1 Baseline characteristics

From: Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction

Parameter Study
Trial 1 Trial 2 Trial 3
DP AS + SP AS + SP AS + SP
Year 2007–2010 2007–2010 2010–2011 2012–2014
No. of patients 59 61 100 83
Location (%)
 Jalalabad 41 (69) 42 (69) 100 (100)
 Takhar 6 (10) 5 (8)
 Faryab 1 (2) 3 (5)
 Kunar 11 (19) 11 (18) 83 (100)
Age (years) (median, range) 11 (2–52) 13 (1–70) 15.5 (3–55) 18 (1–74)
Gender male/female (ratio) 43/16 (2.7) 35/26 (1.3) 60/40 (1.5) 49/34 (1.4)
Body weight (kg) (median, range) 31 (8–87) 35 (7.5-85) 50 (10-72) 49 (10–75)
Median parasitaemia/µl (range) 6760 (1220–90,000) 7200 (900–62,160) 4680 (1000–95,000) 3220 (500–59,520)
No. of patients with gametocytes (%) 13 (22) 29 (48) 19 (19) 42 (51)
Mean axillary temp (°C) ± SD 37.9 ± 1.1 37.9 ± 1.0 38.4 ± 0.8 38.4 ± 0.9
Mean hemoglobin (g/dl) ± SD 11.2 ± 1.3 11.2 ± 1.4 11.50 ± 0.9 11.6 ± 1.9
Mean total drug dose (mg/kg) ± SD
 Artemisinin derivative 6.7 ± 1.2 (DHA) 10.42 ± 1.9 (AS) 10.5 ± 2.0 (AS) 10.5 ± 2.4 (AS)
 Partner drug 53.9 ± 9.3 (PIP) 27.35 ± 11.9 (SUL) 26.8 ± 5.0 (SUL) 27.3 ± 6.1 (SUL)